CeNeS Pharmaceuticals plc (AIM:CEN), the Cambridge-based biopharmaceutical company, today announced that it has entered into a collaboration with Ergomed Clinical Research Limited (“ERGOMED”) to finalise the design and planning of Phase II trials of CeNeS’ novel NMDA antagonist CNS 5161. The trials will be designed to test the compound’s potential as a new treatment for diabetic and post-trauma neuropathic pain, opioid-refractory cancer pain and post-operative pain.
